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Proline hingePs) constitute an important component of the innate immune system in a variety
of organisms. Buforin I is a 39-amino acid AMP that was ﬁrst isolated from the stomach tissue of the Asian
toad Bufo bufo gargarizans. Buforin II is a 21-amino acid peptide that is derived from buforin I and displays an
even more potent antimicrobial activity than its parent AMP. Both peptides share complete sequence identity
with the N-terminal region of histone H2A that interacts directly with nucleic acids. Buforin I is generated
from histone H2A by pepsin-directed proteolysis in the cytoplasm of gastric gland cells. After secretion into
the gastric lumen, buforin I remains adhered to the mucous bioﬁlm that lines the stomach, thus providing a
protective antimicrobial coat. Buforins, which house a helix-hinge-helix domain, kill a microorganism by
entering the cell without membrane permeabilization and thus binding to nucleic acids. The proline hinge is
crucial for the cell penetrating activity of buforins. Buforins also are known to possess anti-endotoxin and
anticancer activities, thus making these peptides attractive reagents for pharmaceutical applications. This
review describes the role of buforins in innate host defense; future research paradigms; and use of these
agents as human therapeutics.
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Amphibians, like other vertebrates, are constantly exposed to
multiple harmful microbes that can easily penetrate the mucosal
surfaces of the respiratory, gastrointestinal, and genitourinary tracts.
Therefore, the capacity to overcome microbial infections is essential
for vertebrate survival [1,2]. Most mucosal surfaces do not contain
abundant phagocytic cells under normal conditions. Thus, surface
epithelial cells are of critical importance inmediating the host's innate
immune response, which is the ﬁrst line of defense against microbial
maladies [3,4]. In response to microbial infection, a variety of host-
defense compounds are secreted from specialized glands on the dorsal82 42 350 2610.
ll rights reserved.surface and into the gut of the amphibian. These include amines,
alkaloids, and cationic antimicrobial peptides (AMPs) [5–7].
AMPs are derived through the proteolysis of precursor proteins/
peptides that are encoded by the host genome and synthesized on
ribosomes. These defense peptides are short (10–50 amino acids) and
contain an overall positive charge (in general, +2 to +9) and a
substantial proportion (N30%) of hydrophobic residues [8–10]. These
properties permit AMPs to fold into amphipathic α-helix and/or β-
sheet structures upon contact with negatively charged microbial
membranes. These structures can then insert themselves into the
membranes of infectious particles and create pores. Energy and ionic
gradients are subsequently lost, and cell lysis occurs within minutes
[11–14]. Furthermore, biological studies of AMPs have demonstrated
that, in addition to killing microorganisms by membrane insertion,
some of these peptides function in regulating cell proliferation, extra-
cellular matrix production, and cellular immune responses [15–17].
Table 1
Amino acid sequences of buforins
Peptide Amino acid sequence
Buforin I AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY
Buforin II TRSSRAGLQFPVGRVHRLLRK
Buforin IIb RAGLQFPVGRLLRRLLRRLLR
Histonin RAGLQFPVGKLLKKLLKRLKR
Fig. 1. Postulated mechanism of buforin I production in toad stomach. In the gastric
mucosal cell, histone H2A is synthesized in excess of the amount required for DNA
packaging and thus accumulates within cytoplasmic secretory granules. Upon secretion
into the gastric lumen, histone H2A is processed by pepsin to the potent antimicrobial
peptide buforin I, which remains adhered to the mucous bioﬁlm that lines the stomach
surface; this provides the stomach with a protective antimicrobial coat. HCl also is
secreted by the gastric mucosal cell and participates in the conversion of inactive
pepsinogen to active pepsin.
Table 2
Antimicrobial activities of buforins
Microorganism Minimal inhibitory concentrationa (μg/mL)
Buforin I Buforin II Buforin IIb Histonin
Gram-positive bacteria
Bacillus subtilis 4 2 1 2
Staphylococcus aureus 4 4 1 2
Streptococcus mutans 8 2 0.5 2
Gram-negative bacteria
Escherichia coli 8 4 1 2
Pseudomonas putida 4 2 2 2
Salmonella typhimurium 4 1 1
Fungi
Candida albicans 4 1 2 2
Cryptococcus neoformans 4 1 1 2
Saccharomyces cerevisiae 4 1 4 2
a Data taken from Refs. [18], [45], and [86].
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the mucosal surfaces from infection and signal host cells to change
their behavior in response to external injury.
Buforin I is a 39-amino acid AMP that was ﬁrst isolated from the
stomach tissue of the Asian toad Bufo bufo gargarizans [18]. Derived
from buforin I, buforin II is a 21-amino acid AMP that displays a more
potent antimicrobial activity than does its parent peptide (Table 1).
The buforins share complete sequence identity with the N-terminal
region of histone H2A, which speciﬁes the protein's DNA binding
activity. Historically, histone function has been studied mainly in
connection with DNA stabilization and regulation of gene expression.
However, a growing collection of evidence suggests that histones are
involved in a multitude of biological functions [19]. For example,
buforin I highlights the role of histones in innate immunity. And
buforin II has attracted the attention of researchers because of its
unique mechanism of antimicrobial action. Indeed, buforins kill a
microorganism by translocating into the cell, without membrane
permeabilization, and thus binding to nucleic acids [20]. This review
focuses on the current status of buforins in terms of their structures;
roles in innate host defense; mechanisms of antimicrobial action; and
other biological activities. The potential exploitation of buforins as
therapeutics is also discussed.
2. Synthesis of buforin I and its role in innate host defense
Compared with other amphibian AMPs, such as magainin 2,
buforin I shows much stronger antimicrobial activities in vitro against
a broad spectrum of microorganisms. In addition to its powerful
antimicrobial activity, a second striking feature of buforin I is that it
shares complete sequence identity with the N-terminal region of
histone H2A [21]. In the eukaryotic nucleus, DNA is packaged as
chromatin, which consists of DNA bound to histones and other
nonhistone proteins. Histones are basic proteins that form a spool
around which nuclear DNA is wrapped, and they constitute the major
protein component of chromatin. Histones are known to function in
chromatin structure formation, nuclear targeting, and the regulation
of gene expression. However, it also has been reported that histones,
especially histone H2A, display weak antimicrobial activity [22–24].
However, the use of histone H2A as an antimicrobial agent by
eukaryotic cells might be problematic, because histone H2A is a large
protein that contains numerous functional domains that carry out its
myriad functions.
In contrast, by virtue of its amphiphaticity and composition of
positively charged amino acids, buforin I houses a domain that
resembles the conserved AMP structural motif more closely than does
the corresponding domain in histone H2A. The observation that
histone H2A serves as a precursor of an AMP has given rise to a series
of intriguing experiments designed to decipher the mode of histone
H2A processing in the toad stomach as part of the innate host defense.
Biochemical and immunohistochemical analyses have revealed that,
in the gastric mucosal cell, histone H2A is synthesized in excess of the
amount required for DNA packaging and accumulates within
cytoplasmic secretory granules. Furthermore, our group has shown
that a fraction of the newly synthesized histone H2A pool is acetylated
and thus targeted for translocation to the nucleus, whereas the
remaining unacetylated histone H2A, upon secretion into the gastric
lumen, is processed by pepsin C isozymes to yield buforin I [25].Buforin I production is known to be closely synchronized with the
secretion of hydrochloric acid and pepsinogen by gastric mucosal
cells; this gastric acid catalyzes the conversion of inactive pepsinogen
to the proteolytically active pepsin (Fig. 1).
As is the case with other anurans, the toad swallows its prey intact
and stores this microbe-laden food in the stomach for some period of
time before digestions begins; thus the secretion of buforin I into the
gastric lumen serves to inhibit bacterial growth. Moreover, after
secretion, buforin I remains adhered to the mucous bioﬁlm that coats
the surface of the stomach (Fig. 1) and thus provides this organwith a
protective antimicrobial coat that works in conjunction with mucosal
immune cells to combat microbial infections. It also has been
suggested that AMPs on the mucosal surfaces of vertebrates aid in
wound repair [26–28].
Buforin I is the ﬁrst histone-derived AMP whose function as an
innate immune effector has been studied in detail. Since then, the role
of histones in innate immunity has been widely appreciated [29–38],
and the proteolytic processing of histone H2A to yield an AMP also has
been reported to occur in vertebrates other than the toad. Parasin I, a
19-amino acid peptide, was isolated from the skin mucus of catﬁsh
[39] and shown to be generated from histone H2A by cathepsin D-
directed proteolysis. The inactive proenzyme procathepsin D is
secreted to the mucosal surface and then processed to the active
1566 J.H. Cho et al. / Biochimica et Biophysica Acta 1788 (2009) 1564–1569mature enzyme (cathepsin D) by a matrix metalloprotease 2 that is
induced in response to epidermal injury [40,41].
3. Structure of buforin II and its mechanism of antimicrobial
action
Buforin II is a 21-residue peptide that is produced from buforin I by
treatment with the endoproteinase Lys-C [18]. Buforin II contains
residues Thr16 to Lys36 of buforin I (Table 1) and exhibits antimicrobial
activity that is twice as potent as that of its parent peptide (Table 2).
Most AMP structure–activity studies of buforins have been performed
with buforin II as a model. The structure of buforin II was determined
using NMR spectroscopy and restrained molecular dynamics [42].
Buforin II adopts a helix-hinge-helix structure in 50% triﬂuoroentha-
nol (TFE); the N-terminal extended α-helix includes residues Arg5 to
Phe10, and the C-terminal α-helix includes residues Val12 to Lys21. The
helices are separated by a proline residue situated at amino acid
position 11 (Fig. 2).
Although buforin II bears a structure similar to those of other
amphiphatic α-helical AMPs, buforin II's mechanism of antimicrobial
action appears to differ from those of AMPs that function by
membrane permeabilization. Confocal ﬂuorescence microscopic ana-
lysis and gel-retardation experiments have revealed that buforin II
kills bacteria without cell lysis and has a strong afﬁnity for DNA and
RNA in vitro [20]. Kobayashi et al. investigated the interaction of
buforin II with phospholipid membranes and compared these results
with those of similar experiments with magainin 2 [43]. These
researchers used equipotent tryptophan-substituted peptides to
ﬂuorometrically monitor peptide–lipid interactions. Control circular
dichroism studies showed that, like magainin 2, buforin II binds
selectively to liposomes composed of acidic phospholipids. However,
the ﬂuorometric experiments revealed that, in contrast to magainin 2,
buforin II translocates across the liposome membranes efﬁciently
without inducing signiﬁcant membrane permeabilization or lipid ﬂip-
ﬂop. Furthermore, the Pro11 residue, which induces a kink in buforin II
α-helix, is the key structural feature required for the buforin II's
unique cell penetrating property.
A subsequent study revealed that buforin II crosses lipid bilayers in
a manner similar to that of magainin 2—via the transient formation of
a peptide–lipid supramolecular complex (toroidal) pore. However, the
presence of Pro11 distorts the helical structure of buforin II,
concentrating ﬁve basic amino acid residues in a limited amphipathic
region (Arg5-Lys21); this structure destabilizes the pore by enhanced
electrostatic repulsion and enables efﬁcient translocation of buforin II
into the microbial cell [44]. The importance of the Pro11 residue also
was demonstrated by a systematic structure–activity relationship
study [45]. In this study, antimicrobial potencies, secondary struc-
tures, and mechanisms of bacterial killing action were assessed for aFig. 2. Ribbon-model representation of the backbone structure of buforin II in 50% TFE.
The N-terminal random coil, the extended helix, the hinge, and the C-terminal regular
helix form an overall amphipathic structure. The amino acid residues are colored as
follows: positively charged residues, red; other hydrophilic residues; blue; proline,
white; other hydrophobic residues, yellow (Reproduced from [45]. Copyright (2000)
National Academy of Sciences, U. S. A.).series of structurally altered synthetic buforin II analogs. The results
revealed that the proline hinge (Pro11) is a key structural factor for the
cell-penetrating property of buforin II, while the cell-penetrating
efﬁciency, which depends on α-helical content, is a critical factor for
determining antimicrobial potency. Indeed, these experiments
showed that only a single amino acid substitution at the Pro11 position
changes buforin II into a membrane-active magainin-like peptide.
Conversely, insertion of a proline-hinge region (Arg5-Gly11) into the
amino-terminal helix of magainin 2 switches this AMP from a
membrane-permeabilizing peptide to a cell-penetrating one.
Because buforin II was shown to bind nucleic acids in vitro, it has
been hypothesized that buforin II kills a microorganism by interacting
with its nucleic acids after translocation across the cell membrane
[20]. Although the proposed mechanism is quite intriguing, many
questions remain to be answered. The connection between nucleic
acid binding and antimicrobial activity has not been demonstrated
directly, and it is unclear whether buforin II and nucleic acids interact
in a speciﬁc manner or whether they only bind to each other because
of their opposite net charges. Uyterhoeven et al. recently characterized
the nucleic acid binding properties of buforin II using molecular
modeling and a ﬂuorescent intercalator displacement assay [46].
These researchers observed that, in addition to non-speciﬁc electro-
static attractions between a cationic peptide and nucleic acids, speciﬁc
side chains (R2 and R20) of buforin II form interactions with DNA that
are stronger than the nonspeciﬁc electrostatic ones. Moreover,
disruption of the buforin II–DNA interactions by substituting basic
residues of buforin II with alanine generally decreases the antimicro-
bial activity of buforin II. This observation supports the assertion that
buforin II kills bacteria through its interaction with nucleic acids,
although it does not preclude buforin II from having other as yet
unidentiﬁed intracellular targets. Indeed, pyrrhocoricin and other
members of the proline-rich AMP family, such as drosocin and
apidaecin, appear to achieve their antimicrobial activity by binding to
the bacterial heat shock protein DnaK [47], preventing chaperone-
assisted host protein folding and inhibiting the strongly related
ATPase activity of DnaK [48].
4. Other biological activities of buforins
Although buforin I and II have been shown primarily to possess a
broad spectrum of antimicrobial activity against many pathogens and
drug-resistant microbes [18,45,49–56], recent studies suggest that
these AMPs have other biological effects as well, such as the inhibition
of botulinum neurotoxins [57] and of tissue factor-initiated coagula-
tion [58]. In fact, several AMPs display anti-endotoxin activity that is
stimulated by binding of the peptide to bacterial lipopolysaccharide
(LPS) and lipoteichoic acid, which results in the prevention of the
sepsis and septic shock associated with the presence of pathogenic
Gram-negative and Gram-positive bacteria [9,59,60]. Similarly,
buforin II is able to prevent lethal endotoxemia in the rat model of
peritonitis [61–63]. In this model, administration of a mono-dose of
buforin II lowers intra-abdominal bacterial concentration and mor-
tality. Furthermore, the concentrations of LPS and the LPS-induced,
sepsis-mediating host cytokine TNF-α also are reduced dramatically
in the blood of septic rats treated with buforin II. In these rats, intra-
abdominal sepsis was induced via cecal ligation and single puncture.
Several AMPs also display anticancer activity [64–69]. One such
peptide, melittin, speciﬁcally kills cells in culture that express high
concentrations of the ras oncogene product [70]. The AMPs cecropin
and magainin also kill neoplastic cells at concentrations lower than
those required to lyse normal host cells, such as peripheral blood
lymphocytes [71,72]. Unlike several other cationic peptides, buforin II
does not exhibit cytotoxic activity against normal eukaryotic cells. For
example, buforin II is nearly nonhemolytic with respect to human
erythrocytes, even at a concentration greater than 200 times the
amount required to inhibit bacterial growth [the so-called minimal
Fig. 3. Antitumor activity of buforin IIb. Spontaneous tumors produced in p53-deﬁcient mice were treated with either phosphate-buffered saline (control) (A) or 20mg/kg of buforin
IIb (B) every 3 days for 2 weeks. Corresponding tumor sections were stained with hematoxylin and eosin (C and D). The cancerous cells are stained dark purple.
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is measured against human ﬁbroblastic TM12 cells, buforin II has
no effect on viability at a concentration of 100 μM [73]. However, a
recent study showed that buforin II and buforin IIb–a synthetic
analog of buforin II that contains a proline hinge between the two
α-helices and a model α-helical sequence at the C-terminus
(3×RLLR)–have selective cytolytic activity against 62 cancer cell lines
with IC50 values (concentration of peptide at 50% cytotoxicity) in the
range of 6 to 24 μg/mL [74]. The remarkable selectivity of buforin IIb
for cancer cells results largely from the inability of the peptide to
penetrate normal cell membranes. Cationic AMPs display selective
toxicity toward bacteria, because their membrane surfaces contain an
abundance of negatively charged phospholipids and polyanionic LPS
[8]. Similarly, the outer surfaces of the plasma membranes of cancer
cells contain high concentrations of negatively charged gangliosides
[75,76]. In contrast, the impenetrable surface of normal mammalian
cell membranes is composed mainly of neutral zwitterionic phos-
pholipids and sterols [77]. Buforin IIb selectively targets cancer cells
through interaction with the cell-surface gangliosides. Buforin IIb
then traverses cancer cell membranes without damaging them and
induces mitochondria-dependent apoptosis [74]. Buforin IIb also
displays powerful cytotoxic activity when injected into solid tumors
in p53-deﬁcient mice (Fig. 3). These results suggest that buforin
IIb may constitute a novel therapeutic agent for the treatment of
cancers.
5. Potential exploitation of buforins as human therapeutics
The emergence and rapid horizontal spread of antibiotic-resistant
traits in bacteria of human and veterinary clinical signiﬁcance have
been a driving force in the search for new classes of antibiotics [78].
AMPs have been regarded as a potential solution to serious worldwide
problems caused by infectious diseases [15]. The potential value of
AMPs for clinical purposes includes their use as single antimicrobial
agents, synergistic agents to existing antibiotics, immunostimulatoryagents, and endotoxin-neutralizing agents [79]. Buforins display many
of the desirable features of a novel antibiotic. They exhibit anti-
microbial activity, withMICs as low as 0.25–4.0 μg/mL, against clinical
isolates of Gram-positive and Gram-negative bacteria, and are
unaffected by classical antibiotic-resistance mutations [49–53,55].
Moreover, buforins are not toxic with respect to mammalian cells,
show synergy with classical antibiotics, neutralize endotoxins, and are
active in animal models [49,54,61–63,73,74].
Despite the fact that buforins show great potential as novel
antibiotics, a number of issues must be solved before these AMPs can
be developed as human therapeutics. For example, short α-helical
peptides, such as the buforins, are cleaved in vivo by endogenous
mammalian proteases, severely reducing an AMP's therapeutic value.
In particular, trypsin-like enzymes attack proteins at basic residues,
which are an obligate feature of AMPs. In this regard, there are
strategies for protecting peptides from proteases, including liposomal
incorporation or chemical modiﬁcation [80]. Recently, Meng and
Kumar reported that incorporation of hexaﬂuoroleucine at selected
sites (Leu18 and Leu19) of buforin II results in simultaneous enhance-
ment of potency and increased resistance to protease degradation.
These observations suggest that ﬂuorination may be an important
strategy for increasing the stability of buforin II [81].
Another impediment in the development of AMPs for therapeutic
use is that it is difﬁcult to produce these peptides in a cost-effective
manner. Because they have relatively high molecular sizes compared
to most other antibiotics, AMPs must be produced using recombinant
techniques in order to keep the cost of production low [82]. Numerous
biological expression systems have been introduced for the cost-
effective production of AMPs [83]. Because of their natural destructive
behavior toward microorganisms and relative sensitivity to proteoly-
tic degradation, AMPs are often produced by fusing the peptides to a
fusion partner protein in the heterologous hosts; this approach
neutralizes the innate bacterial toxicity of AMPs and increases their
expression levels. After puriﬁcation, the recombinant fusion proteins
are cleaved to release the AMPs.
1568 J.H. Cho et al. / Biochimica et Biophysica Acta 1788 (2009) 1564–1569For example, buforin II can be expressed in Escherichia coli by fusing
the AMP to an anionic peptide that neutralizes the positive charges of
buforin II; this modiﬁcation shields host bacterial cells from the lethal
effects of the AMP [84]. In this system, the fusion peptide is expressed
in tandem repeats to increase the production yield. This multimeric
expression is subsequently improved through stabilization of the long
transcripts with a DEAD-box protein or by carrying out recombinant
protein expression in an oxidizing environment using trxB mutant E.
coli as the host cells [85]. In another study a truncated fragment of the
E. coli PurF protein (F4) was used as a fusion partner for histonin, a
synthetic analogue of buforin II Table 1 [86]. F4 reinforces the
formation of inclusion bodies and, hence, prevents the host-lethal
effects and proteolytic degradation of the expressed recombinant
histonin. Using these systems, our group has been able to produce
about 107 mg of buforin II and 167 mg of histonin from 1 L of E. coli
culture.
For the separation of AMPs from its fusion partner, the recom-
binant fusion protein is cleaved with CNBr [84] or furin [86].
However, these chemical or enzymatic cleavage methods are never
100% efﬁcient and make the puriﬁcation of the AMPs complicated
and expensive. Therefore, these techniques cannot yet be performed
on an industrial scale. In this regard, an intein fusion approach offers
an interesting opportunity for the production of AMPs, because
intein can direct its own excision from an intein fusion protein in the
presence of thiols [87,88]. Several groups have used the intein-
mediated system to produce various AMPs [89–92]. However, the
production yields of AMPs using the intein-mediated system were
very low. Therefore, many groups, including us, are currently
working on the improvement of the intein-mediated system or the
development of a novel method to produce AMPs in E. coli as a
natural form without using any chemical or enzymatic cleavage step.
We believe that these efforts may lead to a cost-effective solution for
the mass production of AMPs, so that AMPs may soon fulﬁll their
promise as a solution of overcoming the serious worldwide problems
caused by infectious diseases.
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